key: cord-0858757-6b1u7p35
authors: Ameri, Ahmad; Rahnama, Nazanin; Bozorgmehr, Rama; Mokhtari, Majid; Farahbakhsh, Mohammad; Nabavi, Mahmood; Shoaei, Simin Dokht; Izadi, Hossein; Yousefi Kashi, Amir Shahram; Dehbaneh, Hadiseh Shabanpour; Taghizadeh-Hesary, Farzad
title: Low-dose Whole-lung Irradiation for COVID-19 Pneumonia: Short Course Results
date: 2020-07-21
journal: Int J Radiat Oncol Biol Phys
DOI: 10.1016/j.ijrobp.2020.07.026
sha: 3507c81f0fa6788a4c5127a9f77df6ff782da58d
doc_id: 858757
cord_uid: 6b1u7p35

Abstract Purpose The COVID-19 outbreak is affecting people worldwide. Many of the infected patients suffer from respiratory involvement that may progress to acute respiratory distress syndrome. This pilot study aimed to evaluate the clinical efficacy of low-dose whole-lung radiotherapy in patients with COVID-19 pneumonia. Methods and Materials In this clinical trial, conducted in ***, we enrolled patients with COVID-19 who were older than 60 years and hospitalized to receive supplementary oxygen for their documented pneumonia. Participants were treated with whole-lung irradiation in a single fraction of 0.5 Gy plus the national protocol for the management of COVID-19. Vital signs (including blood oxygenation and body temperature) and laboratory findings (IL-6 and CRP) were recorded before and after irradiation. Results Between 21 May 2020 and 24 June 2020, five patients received whole-lung irradiation. They were followed for 5-7 days to evaluate the response to treatment and toxicities. The clinical and paraclinical findings of four of the five patients (patient #4 became worse and died on day 3) improved on the first day of irradiation. Patient #3 opted-out of the trial on the third day after irradiation. The mean time to discharge was 6 days for the other three patients. No acute radiation-induced toxicity was recorded. Conclusions With a response rate of 80%, whole-lung irradiation in a single fraction of 0.5 Gy had encouraging results in oxygen-dependent patients with COVID-19 pneumonia.

Since the end of 2019, the novel coronavirus disease (COVID-19) has been a major health issue all over the world. It is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has led to more than five hundred thousand deaths as of July 2020 with an estimated crude mortality rate of 3-4% 1-3 . Four phases have been proposed for the pathogenesis of SARS-CoV-2, including suppression of interferon type 1 (IFN-1) production, blockage of IFN-1 signaling, massive inflammatory response (so-called cytokine storm), and immune exhaustion 4 . The lethality of COVID-19 mainly pertains to the cytokine storm-induced thrombotic dysregulation and multi-organ failure 5 . During the cytokine storm, monocytes and macrophages mainly recruit, which may explain elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) 5 . Suppression of cytokine storm can potentially reduce the morbidity and mortality of COVID-19. Recently, the preliminary results of the RECOVERY trial demonstrated that dexamethasone 6 mg given once daily for up to ten days significantly reduced the 28-day mortality among patients with COVID-19 pneumonia receiving invasive mechanical or non-invasive ventilation 6 . Experimental studies have demonstrated the antiinflammatory effect of low dose radiotherapy (LD-RT) by modulating the function of a variety of inflammatory cells, including endothelial cells, polymorphonuclear leukocytes, and macrophages 7-12 . Therefore, LD-RT is considered as an opportunity to block the deadly cytokine storm and save the patients' lives. Herein, we report the outcomes of the first 5 patients with COVID-19 pneumonia who were treated with low-dose whole-lung irradiation at *** Educational Hospital, ***.

Before commencing the study, ethical clearance was obtained from the Ethical Committee of ***University of Medical Sciences*** (Ethical code: ***.REC.1399.073). Prior to assigning the patients to radiotherapy, written informed consent was obtained.

This pilot clinical trial was conducted at *** Educational Hospital to examine the safety and efficacy of single-fraction low-dose whole-lung irradiation in patients with COVID-19 pneumonia (Clinical Trial Registration Number NCT***).

Individuals were enrolled who were more than 60 years old who had clinical manifestations of COVID-19 with a positive polymerase chain reaction (PCR) of the nasopharyngeal swab, antibody test, or radiographic pneumonic consolidations that required oxygen supplementation (with SpO 2 ≤ 93% and/or PaO 2 /FiO 2 ≤ 300 mmHg). For patients who had stable vital signs, we used SpO 2 to estimate PaO 2 13 . The SpO 2 was measured within one hour before the patients' transportation to the RT department using a pulse oximeter (Riester, Germany) by a designated research collaborator.

The patients were kept on room air for 3 minutes to record the SpO 2 at the resting position. Following irradiation, SpO 2 was recorded once a day between 8 to 10 a.m. by the same researcher and the same protocol. The exclusion criteria were patients with hemodynamic instability or requiring mechanical ventilation, with a history of malignancy or heart failure, with contraindication for radiotherapy, with septic shock or end-organ failure, and with severe acute respiratory distress syndrome (with PaO 2 /FiO 2 ≤ 100 mmHg). The primary objectives included change from baseline blood oxygenation (in terms of O2 saturation), the number of hospital/ICU stay days, and the number of intubations performed after radiation treatment. The secondary objectives were changes in laboratory results [including C-reactive peptide (CRP) and IL-6]. Clinical recovery was defined as the first day a subject was discharged or weaned from supplemental oxygen with SpO2 ≥93% in room air. Five of 40 eligible patients signed the consent and entered the study between May 2020 and June 2020. Almost all (33 of 35) of patients who declined to receive low-dose whole-lung irradiation were worried about the radiation-induced malignancy. The other two patients were pessimistic about the efficacy of irradiation. This clinical trial was approved by the Institutional Review Board.

The treatment protocol was low-dose whole-lung irradiation in conjunction with the standard national guideline for the management of COVID-19. So far, seven editions of the national protocol for the management of patients with COVID-19 pneumonia have been published. The sixth and seventh edition was used for our trial. Its principles to manage patients with moderate pulmonary involvement (SpO2 ≤93% on room air or RR >30) were as follows: (1) supplemental oxygen (preferably) via high-flow nasal cannula, (2) unfractionated heparin (UFH) 5,000 units subcutaneously every 8 hours or enoxaparin 40 mg subcutaneously once daily, (3) antibiotics (if clinically indicated, e.g. community-acquired pneumonia), (4) basic supportive care, (5) careful monitoring of patients for clinical indices, (6) dexamethasone 8 mg daily for up to 10 days (at the physician's discretion). 14, 15 All participants were allocated to receive single-fraction 0.5 Gy to the whole lungs. Radiation therapy planning was done on patients' diagnostic CT scans with patients in a supine position using a multislice spiral CT scanner without intravenous contrast. Both lungs were defined as clinical target volume (CTV) and 1 cm was added to create planning target volume (PTV) [including the internal target volume (ITV)].

Treatment planning was done with ISOgray® treatment planning system (DOSIsoft SA, France) that calculates dose using the collapsed cone algorithm (with heterogeneity correction). The prescribed dose to the treatment iso-center (located in the middle of mediastinum) was 0.5 Gy delivered via two opposed anteroposterior (AP) and posteroanterior (PA) open portals. At least 95 and 100 percent of the prescribed dose covered the PTV and CTV, respectively. Considering the extremely low dose of prescription, no restriction was considered for the hot points and the organs at risk including heart, liver, stomach, esophagus, and thyroid gland. The Varian Clinac® 2300 CD with 18 MV photon beams, not equipped with multileaf collimator (MLC), was used to deliver the dose. To decrease the treatment time, no block was considered for the thyroid gland. Although, for the last three patients, the radiation oncologist placed the midline block on the optical field over the upper part of the portals (matched with the lower neck) before the patient enters the treatment room to better protect the thyroid gland. Then, the correction was done for block tray in fourth and fifth patients for both portals. Vital signs, consciousness, performance status, blood oxygenation, CRP, and IL-6 were assessed at baseline and then daily following the irradiation. The body temperature of patients was measured by ward nurse at 6:00 a.m. using tympanic membrane thermometry.

From 21 May 2020 to 24 June 2020, forty patients with COVID-19 pneumonia were asked to participate in the trial and five of them (four males and one female) signed the consent form and received low-dose whole-lung irradiation at the Clinical Oncology Department of *** Hospital. All participants except one (patient #3) were positive for PCR based on a nasopharyngeal swab. Patient #3 was admitted for a loss of consciousness, typical findings of COVID-19 pneumonia in a chest CT scan, and an elevated CRP level. The baseline characteristics of participants are summarized in Table 1 . The patients were between 60 and 84 years old (mean: 71.8 years). All patients had comorbidities, including hypertension in three patients, a history of ischemic heart disease in two patients, and heart failure in one patient. At the time of admission, the median Karnofsky Performance Score (KPS) and Glasgow Coma Scale (GCS) were 60 (range 50-80) and 15 (range 10-15), respectively. LD-RT was delivered one to three days after the admission day (median 2 days). Table 1 .

Of the five initially enrolled patients, four (80%) showed initial improvement in their O 2 saturation and body temperature within one day after irradiation. Of these, one patient (patient #3) chose to opt-out of the trial on the third day of irradiation. The mean time to discharge was 6 days for three patients (patient #1, #2, and #5). Patient #4 started to deteriorate in his O 2 saturation and body temperature on the first day of irradiation and died on the third day after irradiation. The laboratory findings (IL-6 and CRP) were in line with the clinical findings. Regarding IL-6, although the fluctuation pattern was documented in patient #1, the overall trendline was as per clinical findings. Figure 1 demonstrates the change in clinical and laboratory findings following irradiation. During the observation, no acute skin, cardiac, pulmonary, or gastric toxicities were detected. Patient #5 experienced SpO 2 ≥94% while receiving O 2 supply, however, 83% ≤SpO 2 < 87% in room air. At the discretion of his physician and due to the limitation of ventilation facilities, he was discharged on the 7th day after irradiation with medical advice to receive O 2 supply at home. 

Incidentally, none of the patients in our trial received dexamethasone, remdesivir, (hydroxy)chloroquine, or macrolides. Therefore, the effect of these interpreting factors was omitted in the findings. This pilot study had several important findings. First, for oxygen-dependent patients with COVID-19 pneumonia, whole-lung irradiation had a response rate of 80% in terms of clinical and paraclinical findings. Second, not including the one patient opted out of the trial, the clinical condition of patients was evaluable in the remaining four, of whom three were able to leave the hospital (one still on supplemental oxygen) for a clinical recovery rate of 75%. Third, our results showed that LD-RT starts to demonstrate its efficacy from the first day of irradiation. Fourth, CRP changes were consistent with the clinical findings, however, IL-6 showed a fluctuation pattern in one patient but followed the patient's clinical condition. This may be due to the shortterm release of IL-6 upon irradiation 16 . Fifth, despite the clinical efficacy no acute toxicity was reported with LD-RT.

To the best of our knowledge, three other ongoing clinical trials are applying LD-RT in patients with COVID-19 pneumonia. The summary of these trials is presented in Table 2 . Table 2 .

The only available results are from the RESCUE 1-19 trial that was recently published in a non-peer-reviewed journal 8 .

The study detail is summarized in Table 2 . In this pilot study, five patients with COVID-19 pneumonia received wholelung irradiation with a single-fraction of 1.5 Gy. Four of the patients recovered rapidly and were weaned from supplemental oxygen at a mean time of 1.5 days. In all patients, no acute toxicity was reported. Similar findings were reached by our trial in terms of response rate and safety. However, we obtained these results with lower radiation doses. This finding supports the hypothesis that radiation doses as low as 0.5 Gy can modify the immune reaction of COVID-19 pneumonia by activation of macrophages with M2 phenotype 9 . We also included the national protocol for the management of COVID-19 in the treatment plan, which may have affected the results. We went beyond the RESCUE 1-19 trial by examining the body temperature, IL-6, and CRP of patients following irradiation.

According to the national protocol for the management of patients with COVID-19 pneumonia, patients who had SpO2 <90% using non-invasive ventilation with FiO2 >50% were indicated for the intensive care unit (ICU) admission, intubation, and mechanical ventilation. However, due to the limited ventilation facilities, we had to apply the basic ventilation supports with a facial mask ± reservoir bag. This limitation may affect the clinical results of patient #4. We wish to circumvent this effect in the next recruiting patients, by improving the required facilities of our hospital.

Notwithstanding the small sample size, the interim results of the RESCUE 1-19 trial and ours demonstrate that LD-RT may be a successful treatment to save patients with severe COVID-19 pneumonia. Longer follow-up with more patients is needed to confirm this notion. Given the encouraging results of this pilot trial, the Ethical Committee of *** University of Medical Sciences allowed continuing the trial using 1.0 Gy whole-lung irradiation.

Our World in Data. Mortality risk of COVID-19

Cancer care delivery challenges amidst coronavirus disease-19 (COVID-19) outbreak: specific precautions for cancer patients and cancer care providers to prevent spread

World Health Organization. Coronavirus disease 2019 (COVID-19) situation report -46

The powerful immune system against powerful COVID-19: A hypothesis

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

Anti-inflammatory effects of low-dose radiotherapy

Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day-7 Interim Analysis of a Registered Clinical Trial

Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a costeffective anti-inflammatory treatment. Clinical and Translational Radiation Oncology

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Is low dose radiation therapy a potential treatment for COVID-19 pneumonia? Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Roentgen therapy of lobar pneumonia

Imputation of partial pressures of arterial oxygen using oximetry and its impact on sepsis diagnosis

Ministry of Health. The flowchart for diagnosis and treatment of COVID-19 in outpatient and inpatient settings

Cytokines, fatigue, and cutaneous erythema in early stage breast cancer patients receiving adjuvant radiation therapy